Bulk anti-human EGFR antibody (EGFR.1)
ichorbio’s bulk anti-human EGFR antibody (EGFR.1) is manufactured in a cGMP compliant facility. ichorbio’s low endotoxin antibodies have half the endotoxin of comparable antibodies from our competitors at less than 1.0 EU/mg. If ichorbio’s low endotoxin antibodies are not low enough we also offer ultra low endotoxin antibodies which have even less endotoxin (<0.75EU/mg) at an even higher purity (98% versus 95%). ichorbio offers Amazon vouchers or donations to the NC3Rs for reviews of this product: click here for more information. ichorbio: the best antibodies for in vivo research.
Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, ERBB, ERBB1, HER1
Bulk anti-human EGFR antibody (EGFR.1) recognizes the (Mr 170 kDa) extracellular domain of the epidermal growth factor receptor on many cell surfaces. The EGFR mediates the initial response of cells to EGF. It has an extracellular region which binds EGF and an intracellular region which exhibits tyrosine kinase activity. The receptor phosphorylates a number of protein substrates in addition to mediating autophosphorylation
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. EGFR (epidermal growth factor receptor) exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor A (TGFA) (note, a full list of the ligands able to activate EGFR and other members of the ErbB family is given in the ErbB article). ErbB2 has no known direct activating ligand, and may be in an activated state constitutively or become active upon heterodimerization with other family members such as EGFR. Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer – although there is some evidence that preformed inactive dimers may also exist before ligand binding. In addition to forming homodimers after ligand binding, EGFR may pair with another member of the ErbB receptor family, such as ErbB2/Her2/neu, to create an activated heterodimer. There is also evidence to suggest that clusters of activated EGFRs form, although it remains unclear whether this clustering is important for activation itself or occurs subsequent to activation of individual dimers.
A431 cultured cells
1.0 – 5.0 mg/ml
0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added. BSA and Azide free.
>95% by SDS-PAGE and HPLC
>98% by SDS-PAGE and HPLC
≤ 1.0 EU/mg as determined by the LAL method
≤ 0.75 EU/mg as determined by the LAL method
Aggregation level ≤ 5%
Aggregation level ≤ 1%
We use the IMPACT test generated by IDEXX Laboratories to guarantee our Ultra Low Endotoxin antibodies are pathogen free. Our mouse antibodies are tested for:
Mouse hepatitis virus
Pneumonia virus of mice
Minute virus of mice
Mouse parvovirus (MPV1-5)
Theiler’s murine encephalomyelitis virus
Lymphocytic choriomeningitis virus
Lactate dehydrogenase-elevating virus
Mouse adenovirus (MAD1, MAD2)
Mouse thymic virus
Corynebacterium spp. (HAC2)
This antibody is stable for at least 4 weeks when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at – 20°C or -80°C. Avoid repeated freeze thaw cycles.
Flow Cytometry, Immunocytochemistry, Immunofluorescence, IHC (Frozen), Immunoprecipitation, Neutralization, IP-Mass Spectrometry, Western Blot
Each investigator should determine their own optimal working dilution for specific applications.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.